The spatial immune geography of resectable non-small-cell lung cancer: ecosystem architecture of perioperative immunotherapy response and relapse
- 1Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University
- 2Department of Respiratory and Critical Care Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University
Abstract
Perioperative immune-checkpoint blockade has improved pathological and event-free outcomes in resectable non-small-cell lung cancer (NSCLC), but benefit remains heterogeneous and current biomarkers do not reliably distinguish tumor eradication from transient control or future relapse. This limitation partly reflects how tumors are measured: programed death ligand 1 expression, tumor mutational burden and bulk immune-cell abundance compress a spatially organized ecosystem into summary values. Here, we define the spatial immune geography of resectable NSCLC across four coupled scales: intratumor territories, cellular neighborhoods, regional immune structures—including tertiary lymphoid structures and tumor-draining lymph nodes—and longitudinal transitions from pretreatment biopsy to resection, molecular residual disease and recurrence. We critically synthesize human evidence linking T-cell access, antigen-presentation circuits, B-cell and tertiary-lymphoid organization, and stromal, myeloid and hypoxic niches to perioperative immunotherapy response. We further distinguish pretreatment predictors from treatment-induced pharmacodynamic changes and explain why pathological response and biological cure are related but non-equivalent endpoints. On this basis, we propose a testable spatial-immune-resilience framework comprising eradication-permissive, persistence-prone and escape-permissive ecosystems. We also evaluate how multiplex imaging, spatial transcriptomics, digital spatial profiling, anatomically registered single-cell analysis and computational pathology differ in biological reach and translational readiness. Finally, we outline an assay-to-decision validation pathway that integrates standardized multiregion tissue sampling, tumor-draining lymph nodes and circulating tumor DNA. Spatial profiling is unlikely to transform perioperative care through maximal molecular resolution alone; its clinical value will depend on reproducible, parsimonious measurements that improve decisions beyond stage, pathology and molecular residual disease.
Related
- Macrophage state in neoadjuvant and perioperative immunotherapy resistance in resectable NSCLC: a critical appraisal of strategies from CSF1R and CD47–SIRPα to CAR-macrophages
- Tertiary lymphoid structures in luminal gastrointestinal cancers: biological circuits, spatial architecture, and biomarkers in the perioperative immunotherapy era
- From TLS architecture to functional immune niches: division of labor among CAFs, HEVs, and antigen-presenting cells in cancer immunotherapy
- 445 Co-mutation architecture shapes immunotherapy outcomes in KRAS-mutant NSCLC: real-world evidence from AACR GENIE BPC cohort
- Beyond elevation: climate, geography, and the diversification of Himalayan Rhododendrons. A commentary on ‘Phenotypic and genetic variation among Rhododendron arboreum species complex widely distributed throughout the Himalayas suggests an obscure geographic origin of the clade’
BibTeX
@article{qi2026spatial,
title = {{The spatial immune geography of resectable non-small-cell lung cancer: ecosystem architecture of perioperative immunotherapy response and relapse}},
author = {Siwei Qi and Xing Zhou and Chengmeng Liu and Qianhui Zhou},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2012133},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2012133/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The spatial immune geography of resectable non-small-cell lung cancer: ecosystem architecture of perioperative immunotherapy response and relapse
AU - Siwei Qi
AU - Xing Zhou
AU - Chengmeng Liu
AU - Qianhui Zhou
PY - 2026
DA - 2026/11/03
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2012133
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2012133/full
AB - Perioperative immune-checkpoint blockade has improved pathological and event-free outcomes in resectable non-small-cell lung cancer (NSCLC), but benefit remains heterogeneous and current biomarkers do not reliably distinguish tumor eradication from transient control or future relapse. This limitation partly reflects how tumors are measured: programed death ligand 1 expression, tumor mutational burden and bulk immune-cell abundance compress a spatially organized ecosystem into summary values. Here, we define the spatial immune geography of resectable NSCLC across four coupled scales: intratumor territories, cellular neighborhoods, regional immune structures—including tertiary lymphoid structures and tumor-draining lymph nodes—and longitudinal transitions from pretreatment biopsy to resection, molecular residual disease and recurrence. We critically synthesize human evidence linking T-cell access, antigen-presentation circuits, B-cell and tertiary-lymphoid organization, and stromal, myeloid and hypoxic niches to perioperative immunotherapy response. We further distinguish pretreatment predictors from treatment-induced pharmacodynamic changes and explain why pathological response and biological cure are related but non-equivalent endpoints. On this basis, we propose a testable spatial-immune-resilience framework comprising eradication-permissive, persistence-prone and escape-permissive ecosystems. We also evaluate how multiplex imaging, spatial transcriptomics, digital spatial profiling, anatomically registered single-cell analysis and computational pathology differ in biological reach and translational readiness. Finally, we outline an assay-to-decision validation pathway that integrates standardized multiregion tissue sampling, tumor-draining lymph nodes and circulating tumor DNA. Spatial profiling is unlikely to transform perioperative care through maximal molecular resolution alone; its clinical value will depend on reproducible, parsimonious measurements that improve decisions beyond stage, pathology and molecular residual disease.
SN - 1664-3224
ER -